CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

Berlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational ...

The approval was based on results from a Phase IIb trial demonstrating a 15.5-month median overall survival on Ziihera.

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than 100 ...

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

The firm submitted data showing that more than 70 percent of patients with HER2-mutated NSCLC who hadn't received anti-HER2 therapy responded to sevabertinib.